Mark Ragosa - 01 Apr 2026 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
03 Apr 2026, 16:40:09 UTC
Prior SEC filing
11 Mar 2026
Next SEC filing
08 Apr 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Douglas Barry, Attorney-in-Fact
Filing notes and source

Key filing fact

Mark Ragosa filed Form 4 for Kiniksa Pharmaceuticals International, plc (KNSA) on 03 Apr 2026.

Key facts

  • This page summarizes Mark Ragosa's Form 4 filing for Kiniksa Pharmaceuticals International, plc (KNSA).
  • 8 reported transactions and 6 derivative rows are listed below.
  • Accepted by SEC: 03 Apr 2026, 16:40.

Change

  • Previous filing in this sequence was filed on 11 Mar 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001835458 Primary reporting owner

Ragosa Mark

Relationship
CHIEF FINANCIAL OFFICER
Address
C/O KINIKSA PHARMACEUTICALS INT'L, 105 PICCADILLY, SECOND FLOOR, LONDON, UNITED KINGDOM
Signature
/s/ Douglas Barry, Attorney-in-Fact
Signature date
03 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KNSA transaction

Class A Ordinary Share

Options Exercise

Transaction value
Shares
+5,187
Change %
+43%
Price
Shares after
17,273
Date
01 Apr 2026
Ownership
Direct
Footnotes
F1
KNSA transaction

Class A Ordinary Share

Tax liability

Transaction value
Shares
-2,510
Change %
-15%
Price
$48.13*
Shares after
14,763
Date
01 Apr 2026
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KNSA transaction Derivative

Share Option

Award

Transaction value
Shares
+31,150
Change %
Price
$0.000000*
Shares after
31,150
Date
01 Apr 2026
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
31,150
Exercise price
$48.13
Footnotes
F2
KNSA transaction Derivative

Restricted Share Unit

Award

Transaction value
Shares
+7,800
Change %
Price
$0.000000*
Shares after
7,800
Date
01 Apr 2026
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
7,800
Exercise price
Footnotes
F1, F3
KNSA transaction Derivative

Performance Share Unit

Award

Transaction value
Shares
+15,600
Change %
Price
$0.000000*
Shares after
15,600
Date
01 Apr 2026
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
15,600
Exercise price
Footnotes
F4, F5
KNSA transaction Derivative

Restricted Share Unit

Options Exercise

Transaction value
Shares
-1,750
Change %
-50%
Price
$0.000000*
Shares after
1,750
Date
01 Apr 2026
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
1,750
Exercise price
Footnotes
F1, F6
KNSA transaction Derivative

Restricted Share Unit

Options Exercise

Transaction value
Shares
-1,591
Change %
-33%
Price
$0.000000*
Shares after
3,182
Date
01 Apr 2026
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
1,591
Exercise price
Footnotes
F1, F7
KNSA transaction Derivative

Restricted Share Unit

Options Exercise

Transaction value
Shares
-1,846
Change %
-25%
Price
$0.000000*
Shares after
5,536
Date
01 Apr 2026
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
1,846
Exercise price
Footnotes
F1, F8
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 8 footnotes

Footnote F1

Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

Footnote F2

The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April1, 2026.

Footnote F3

The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2026, and each yearly anniversary thereafter.

Footnote F4

Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Ordinary Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee

Footnote F5

Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2029, unless such date falls on a non-business date, in which case the next business date shall apply.

Footnote F6

The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2023.

Footnote F7

The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2024.

Footnote F8

The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2025.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .